MedTrace Logo

PET / MR With PSMA for Diagnosis and Staging of Hepatocellular Carcinoma

NCT05580835 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-10-14

No results posted yet for this study

Summary

Assess the rate and degree of PSMA uptake in patients with hepatocellular carcinoma submitted to PET/MRI scans. The objective is to evaluate its value on diagnosis and staging of HCC.

Conditions

  • Carcinoma, Hepatocellular

Interventions

DIAGNOSTIC_TEST

PET MRI with PSMA

A whole-body PET using PSMA as a radiotracer associated to an upper abdomen MRI with gadoxetic acid as contrast agent

Sponsors & Collaborators

  • GE Healthcare

    collaborator INDUSTRY

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • Irai S Oliveira, MD · University of Sao Paulo

  • Carlos Buchpiguel, PhD · University of Sao Paulo

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-05
Primary Completion
2023-09-04
Completion
2024-09-04

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05580835 on ClinicalTrials.gov